We are live on ! Find out more
APRE icon

Aprea Therapeutics
APRE

33 hedge funds and large institutions have $1.52M invested in Aprea Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,670% more call options, than puts

Call options by funds: $477K | Put options by funds: $10K

10% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 10

0.09% less ownership

Funds ownership: 0.55% → 0.46% (-0.09%)

18% less funds holding

Funds holding: 40 → 33 (-7)

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

66% less capital invested

Capital invested by funds: $4.5M → $1.52M (-$2.98M)

Holders
33
Holders Change
-7
Holders Change %
-17.5%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
11
Reduced
10
Closed
10
Calls
$477K
Puts
$10K
Net Calls
+$467K
Net Calls Change
-$616K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$121K
2
Jane Street
Jane Street
New York
+$82.9K
3
Two Sigma Investments
Two Sigma Investments
New York
+$48.1K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$37.9K
5
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$23.1K

Top Sellers

Rank Fund Capital Flow
1
KCM
Kennedy Capital Management
Missouri
-$623K
2
Citadel Advisors
Citadel Advisors
Florida
-$67.1K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$56.9K
4
PP
PDT Partners
New York
-$55K
5
Goldman Sachs
Goldman Sachs
New York
-$54K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
26
UBS Group
Switzerland
$8K +$5.86K +254 +97%
Millennium Management
27
Millennium Management
New York
$8K +$11.8K +513 New
SWM
28
Sugarloaf Wealth Management
Georgia
$4K +$4.03K +175 +233%
Federated Hermes
29
Federated Hermes
Pennsylvania
$3K +$161 +7 +4%
KCM
30
Kennedy Capital Management
Missouri
– -$623K -16,740 Closed
JP Morgan Chase
31
JP Morgan Chase
New York
– -$34K -1,475 Closed
PP
32
PDT Partners
New York
– -$55K -1,472 Closed
Goldman Sachs
33
Goldman Sachs
New York
– -$54K -1,455 Closed
CSS
34
Cubist Systematic Strategies
Connecticut
– -$38K -1,029 Closed
GTCM
35
Gyon Technologies Capital Management
New Jersey
– -$38K -1,029 Closed
MFG
36
Magnus Financial Group
New York
– -$28K -743 Closed
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
– -$22K -585 Closed
Bank of America
38
Bank of America
North Carolina
– -$4.59K -199 -95%
Simplex Trading
39
Simplex Trading
Illinois
– -$2.05K -89 Closed
Citigroup
40
Citigroup
New York
– -$1K -25 Closed
Wells Fargo
41
Wells Fargo
California
– +$576 +25 +500%
1
2

APRE Hedge Fund Activity: Q2 2022 in Review

33 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q2 2022, worth a combined $1.52M — down 66% from $4.5M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of APRE and 4 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 11 added.

The largest buyer was Morgan Stanley, adding an estimated $121K. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $623K sold.

  • 33 institutional investors held Aprea Therapeutics (APRE) as of Q2 2022, down from 40 in Q1 2022.
  • Funds reported $1.52M of Aprea Therapeutics stock for Q2 2022, down 66% quarter-over-quarter.
  • 4 funds opened new Aprea Therapeutics positions in Q2 2022 and 10 closed out, a net change of -6 holders.
  • The largest Aprea Therapeutics buyer in Q2 2022 was Morgan Stanley, an estimated $121K added.
  • The largest Aprea Therapeutics seller in Q2 2022 was Kennedy Capital Management, an estimated $623K sold.

Based on aggregated 13F filings for Q2 2022.